Découvrir nos portefeuilles : Investisseur PEA |  International |  Trader
Accès Membre / Client

Accueil Zonebourse  >  Actions  >  Nasdaq  >  Dendreon Corporation    DNDNQ   US24823Q1076

DENDREON CORPORATION (DNDNQ)

24
Cours en différé. Temps Différé Nasdaq - 26/03 20:56:53
0.04 USD   --.--%
23/02 La stratégie de Valeant saluée en Bourse
2014 Les valeurs à suivre à Wall Street (actualisé)
2014DENDREON CORPOR : publication des résultats trimestriels
SynthèseCotationsGraphiquesActualitésAnalysesAgendaSociétéFinancesConsensusRévisionsDérivésFondsCommunauté 
Métier
Logo Dendreon Corporation
Discovers, develops and commercializes novel products for the treatment of cancer

Dendreon Corp. is a biotechnology company, which focuses on discovery, development and commercialization of novel therapeutics that improves cancer treatment options for patients.

The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types.

It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers.

Dendreon was founded by Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA.

Nombre d'employés : 755 personnes.
Ventes par activité
20122013Delta
USD (en Millions)%USD (en Millions)%
Novel Therapeutics325,53100%283,75100% -14.73%
Ventes par région
20122013Delta
USD (en Millions)%USD (en Millions)%
United States325,53100%283,75100% -14.73%
Dirigeants
Nom AgeDepuisTitre
W. Thomas Amick712014President, Chief Executive Officer & Director
Douglas G. Watson692000Chairman
Gregory R. Cox, CPA482005Chief Financial Officer, Treasurer & VP
William Monteith-2009Executive Vice President-Technical Operations
Andrew S. Sandler, MD-2014Chief Medical Officer & Executive Vice President
Bogdan Dziurzynski PhD, MBA652001Independent Director
Susan B. Bayh542003Independent Director
David L. Urdal, PhD641995Director
David C. Stump, MD642010Independent Director
Dennis M. Fenton, PhD622011Independent Director
Actionnaires
Nom Actions%
Point72 Asset Management LP 3 000 000 1,89%
PRIMECAP Management Co. 2 390 000 1,51%
Goldman Sachs & Co. (Private Banking) 2 081 250 1,31%
Scopia Capital Management LLC 1 824 183 1,15%
John H. Johnson 1 704 624 1,07%
The Vanguard Group, Inc. 1 628 666 1,03%
Norges Bank Investment Management 1 155 140 0,73%
Aristeia Capital LLC 1 000 000 0,63%
Geode Capital Management LLC 833 092 0,52%
Susquehanna Financial Group LLLP 760 355 0,48%
Secteur
Santé
Recherche pharmaceutique et médicale
 Recherche biotechnologique et médicale
  Recherche biotechnologique et médicale
   Recherche biotechnologique et médicale - NCA
Publicité
Secteur Recherche biotechnologique et médicale
CroissanceRentabilité
PHARMACYCLICS, IN..
INCYTE CORPORATIO..
ALKERMES PLC
ALNYLAM PHARMACEU..
QUINTILES TRANSNA..
UNITED THERAPEUTI..
CELLTRION, INC.
ISIS PHARMACEUTIC..
PUMA BIOTECHNOLOG..
-
QIAGEN NV
SEATTLE GENETICS,..
INTREXON CORP
ICON PLC
CHARLES RIVER LAB..
BIO-TECHNE CORP
PAREXEL INTERNATI..
BB BIOTECH AG
-
SYNAGEVA BIOPHARM..
ACADIA PHARMACEUT..
WUXI PHARMATECH (..
Secteur Recherche biotechnologique et médicale
Dendreon Corporation : Connexions
Nora Therapeutics, Inc.
Emmis Operating Co.
Viral Logic Systems Technology Corp.
Napo Pharmaceuticals, Inc.
The Chartered Institute of Management Accountants
Pittencrieff Glen Associates
Keck Graduate Institute of Applied Life Sciences
BioRexis Pharmaceutical Corp.
Rutgers University (New Jersey)
Biolex Therapeutics, Inc.
Transport Pharmaceuticals, Inc.
Earlham College
The Biotechnology Institute
Fenton & Associates LLC
The Scripps Research Institute
© 2015 People , Fundamentals and Ownership   
Rechercher
Contactez-nous
+33 (0)4 78 30 41 42
Rejoignez
126 465 membres
Cotations dynamiques  
ON
| OFF